2018 American Heart Association Focused Update on Pediatric Advanced Life Support: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care

Jonathan P. Duff, Alexis Topjian, Marc D. Berg, Melissa Chan, Sarah E. Haskell, Benny L. Joyner, Javier J. Lasa, Sondra J. Ley, Tia T. Raymond, Robert M. Sutton, Mary Fran Hazinski, Dianne L. Atkins

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

This 2018 American Heart Association focused update on pediatric advanced life support guidelines for cardiopulmonary resuscitation and emergency cardiovascular care follows the 2018 evidence review performed by the Pediatric Task Force of the International Liaison Committee on Resuscitation. It aligns with the International Liaison Committee on Resuscitation's continuous evidence review process, and updates are published when the group completes a literature review based on new published evidence. This update provides the evidence review and treatment recommendation for antiarrhythmic drug therapy in pediatric shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. As was the case in the pediatric advanced life support section of the "2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care," only 1 pediatric study was identified. This study reported a statistically significant improvement in return of spontaneous circulation when lidocaine administration was compared with amiodarone for pediatric ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. However, no difference in survival to hospital discharge was observed among patients who received amiodarone, lidocaine, or no antiarrhythmic medication. The writing group reaffirmed the 2015 pediatric advanced life support guideline recommendation that either lidocaine or amiodarone may be used to treat pediatric patients with shock-refractory ventricular fibrillation or pulseless ventricular tachycardia.

Original languageEnglish (US)
Pages (from-to)e731-e739
JournalCirculation
Volume138
Issue number23
DOIs
StatePublished - Dec 4 2018

Fingerprint

Cardiopulmonary Resuscitation
Emergency Medical Services
Guidelines
Pediatrics
Amiodarone
Ventricular Fibrillation
Ventricular Tachycardia
Lidocaine
Heart Arrest
Resuscitation
Shock
Anti-Arrhythmia Agents
Advisory Committees
Drug Therapy
Survival

Keywords

  • advanced cardiac life support
  • AHA Scientific Statements
  • anti-arrhythmia agents
  • cardiopulmonary resuscitation
  • heart arrest
  • pediatrics
  • tachycardia, ventricular
  • ventricular fibrillation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

2018 American Heart Association Focused Update on Pediatric Advanced Life Support : An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. / Duff, Jonathan P.; Topjian, Alexis; Berg, Marc D.; Chan, Melissa; Haskell, Sarah E.; Joyner, Benny L.; Lasa, Javier J.; Ley, Sondra J.; Raymond, Tia T.; Sutton, Robert M.; Hazinski, Mary Fran; Atkins, Dianne L.

In: Circulation, Vol. 138, No. 23, 04.12.2018, p. e731-e739.

Research output: Contribution to journalArticle

Duff, Jonathan P. ; Topjian, Alexis ; Berg, Marc D. ; Chan, Melissa ; Haskell, Sarah E. ; Joyner, Benny L. ; Lasa, Javier J. ; Ley, Sondra J. ; Raymond, Tia T. ; Sutton, Robert M. ; Hazinski, Mary Fran ; Atkins, Dianne L. / 2018 American Heart Association Focused Update on Pediatric Advanced Life Support : An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. In: Circulation. 2018 ; Vol. 138, No. 23. pp. e731-e739.
@article{201792b87c8f454caf52d9b48b41792c,
title = "2018 American Heart Association Focused Update on Pediatric Advanced Life Support: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care",
abstract = "This 2018 American Heart Association focused update on pediatric advanced life support guidelines for cardiopulmonary resuscitation and emergency cardiovascular care follows the 2018 evidence review performed by the Pediatric Task Force of the International Liaison Committee on Resuscitation. It aligns with the International Liaison Committee on Resuscitation's continuous evidence review process, and updates are published when the group completes a literature review based on new published evidence. This update provides the evidence review and treatment recommendation for antiarrhythmic drug therapy in pediatric shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. As was the case in the pediatric advanced life support section of the {"}2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,{"} only 1 pediatric study was identified. This study reported a statistically significant improvement in return of spontaneous circulation when lidocaine administration was compared with amiodarone for pediatric ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. However, no difference in survival to hospital discharge was observed among patients who received amiodarone, lidocaine, or no antiarrhythmic medication. The writing group reaffirmed the 2015 pediatric advanced life support guideline recommendation that either lidocaine or amiodarone may be used to treat pediatric patients with shock-refractory ventricular fibrillation or pulseless ventricular tachycardia.",
keywords = "advanced cardiac life support, AHA Scientific Statements, anti-arrhythmia agents, cardiopulmonary resuscitation, heart arrest, pediatrics, tachycardia, ventricular, ventricular fibrillation",
author = "Duff, {Jonathan P.} and Alexis Topjian and Berg, {Marc D.} and Melissa Chan and Haskell, {Sarah E.} and Joyner, {Benny L.} and Lasa, {Javier J.} and Ley, {Sondra J.} and Raymond, {Tia T.} and Sutton, {Robert M.} and Hazinski, {Mary Fran} and Atkins, {Dianne L.}",
year = "2018",
month = "12",
day = "4",
doi = "10.1161/CIR.0000000000000612",
language = "English (US)",
volume = "138",
pages = "e731--e739",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "23",

}

TY - JOUR

T1 - 2018 American Heart Association Focused Update on Pediatric Advanced Life Support

T2 - An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care

AU - Duff, Jonathan P.

AU - Topjian, Alexis

AU - Berg, Marc D.

AU - Chan, Melissa

AU - Haskell, Sarah E.

AU - Joyner, Benny L.

AU - Lasa, Javier J.

AU - Ley, Sondra J.

AU - Raymond, Tia T.

AU - Sutton, Robert M.

AU - Hazinski, Mary Fran

AU - Atkins, Dianne L.

PY - 2018/12/4

Y1 - 2018/12/4

N2 - This 2018 American Heart Association focused update on pediatric advanced life support guidelines for cardiopulmonary resuscitation and emergency cardiovascular care follows the 2018 evidence review performed by the Pediatric Task Force of the International Liaison Committee on Resuscitation. It aligns with the International Liaison Committee on Resuscitation's continuous evidence review process, and updates are published when the group completes a literature review based on new published evidence. This update provides the evidence review and treatment recommendation for antiarrhythmic drug therapy in pediatric shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. As was the case in the pediatric advanced life support section of the "2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care," only 1 pediatric study was identified. This study reported a statistically significant improvement in return of spontaneous circulation when lidocaine administration was compared with amiodarone for pediatric ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. However, no difference in survival to hospital discharge was observed among patients who received amiodarone, lidocaine, or no antiarrhythmic medication. The writing group reaffirmed the 2015 pediatric advanced life support guideline recommendation that either lidocaine or amiodarone may be used to treat pediatric patients with shock-refractory ventricular fibrillation or pulseless ventricular tachycardia.

AB - This 2018 American Heart Association focused update on pediatric advanced life support guidelines for cardiopulmonary resuscitation and emergency cardiovascular care follows the 2018 evidence review performed by the Pediatric Task Force of the International Liaison Committee on Resuscitation. It aligns with the International Liaison Committee on Resuscitation's continuous evidence review process, and updates are published when the group completes a literature review based on new published evidence. This update provides the evidence review and treatment recommendation for antiarrhythmic drug therapy in pediatric shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. As was the case in the pediatric advanced life support section of the "2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care," only 1 pediatric study was identified. This study reported a statistically significant improvement in return of spontaneous circulation when lidocaine administration was compared with amiodarone for pediatric ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. However, no difference in survival to hospital discharge was observed among patients who received amiodarone, lidocaine, or no antiarrhythmic medication. The writing group reaffirmed the 2015 pediatric advanced life support guideline recommendation that either lidocaine or amiodarone may be used to treat pediatric patients with shock-refractory ventricular fibrillation or pulseless ventricular tachycardia.

KW - advanced cardiac life support

KW - AHA Scientific Statements

KW - anti-arrhythmia agents

KW - cardiopulmonary resuscitation

KW - heart arrest

KW - pediatrics

KW - tachycardia, ventricular

KW - ventricular fibrillation

UR - http://www.scopus.com/inward/record.url?scp=85058098182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058098182&partnerID=8YFLogxK

U2 - 10.1161/CIR.0000000000000612

DO - 10.1161/CIR.0000000000000612

M3 - Article

C2 - 30571264

AN - SCOPUS:85058098182

VL - 138

SP - e731-e739

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 23

ER -